Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Studies with ZD1839 in preclinical models.

Francis M Sirotnak1

  • 1Laboratory for Molecular Therapeutics, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

Seminars in Oncology
|March 20, 2003
PubMed
Summary

ZD1839 (Iressa) is a targeted therapy inhibiting epidermal growth factor receptor-tyrosine kinase (EGFR-TK). This drug demonstrated significant antitumor activity across various solid tumors in preclinical models, supporting its clinical development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

E2F site in the essential promoter region does not confer S phase-specific transcription of the ABCC10 gene in human prostate cancer cells.

Acta biochimica Polonica·2017
Same author

Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2008
Same author

Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics.

The Journal of clinical investigation·2004
Same author

Regulation of transcription of the human MRP7 gene. Characteristics of the basal promoter and identification of tumor-derived transcripts encoding additional 5' end heterogeneity.

Gene·2004
Same author

The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.

Clinical cancer research : an official journal of the American Association for Cancer Research·2003
Same author

A new human peptide deformylase inhibitable by actinonin.

Biochemical and biophysical research communications·2003

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor-tyrosine kinase (EGFR-TK) signaling pathways drive cancer cell proliferation, invasion, and survival.
  • Selective inhibition of EGFR-TK represents a promising therapeutic strategy for solid tumors.

Purpose of the Study:

  • To evaluate the preclinical antitumor activity of ZD1839 (Iressa), a selective EGFR-TK inhibitor.
  • To assess the efficacy of ZD1839 as a single agent and in combination with chemotherapy or radiotherapy.

Main Methods:

  • Preclinical studies using cancer cell lines and human tumor xenografts.
  • Assessment of ZD1839's effect on tumor growth inhibition and regression across various solid tumor types.
  • Evaluation of combination therapy with cytotoxic agents or radiotherapy.

Related Experiment Videos

Main Results:

  • ZD1839 demonstrated growth inhibition in lung, prostate, breast, colon, and ovarian cancer xenografts, irrespective of EGFR expression levels.
  • A431 vulvar carcinoma xenografts, with high EGFR expression, showed tumor regression.
  • Combination therapy with ZD1839 resulted in additive or synergistic antitumor activity.
  • Inhibition of EGFR-TK delayed tumor development in a transgenic model and affected early-stage lesions.

Conclusions:

  • ZD1839 exhibits broad-spectrum preclinical antitumor activity against solid tumors.
  • Targeting EGFR-TK with ZD1839 is a viable strategy for cancer therapy, including early-stage disease.
  • Further clinical investigation of ZD1839 is warranted based on its diverse and potent preclinical effects.